OTC Markets OTCQB - Delayed Quote ? USD Vivos Inc. (RDGL) Follow Compare 0.1217 +0.0017 (+1.42%) At close: November 1 at 4:00 PM EDT All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Vivos Inc. Certifies New Clinic for IsoPet? Precision Radionuclide TherapyTM Richland WA N, Oct. 18, 2024 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc. Certifies new clinic for IsoPet therapy. NorthStar Vets - Veterinary Emergency & Trauma Specialty Center in Robbinsville, NJ. provides 24/7/365 emergency, trauma, and critical care and a suite of veterinary specialty services for small animals. They have been approved and licensed to offer IsoPet Precision Radionuclide Therapy as a cancer treatment for small animals. Dr. Korenko stated “An important objective i GlobeNewswire ? 14 days ago RDGL +1.42% Vivos Inc. Extended its IsoPet? Precision Radionuclide TherapyTM to Exotics Richland WA N, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc. We recently treated our first exotic animal, a ferret, with encouraging results, seeing a considerable reduction in tumor size after three weeks. Treatment options for cancer in small exotic animals remain limited, and the current standard of care—surgical tumor removal—can be too invasive for exotic animals. Dr. Korenko commented, “While we have experience treating cats, dogs, and horses, there is a growing n GlobeNewswire ? last month RDGL +1.42% Vivos Inc. Provides IDE Submission Status Update – Conversion to Pre-Sub Filing Accepted by the FDA Richland WA, July 29, 2024 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc. Provides IDE Submission Status Update The FDA has been working diligently to review the extensive amount of material that we provided in our IDE submission within the 30-day statutory time limit. We have been in regular communication with the FDA and provided responses to five sets of Interactive Review Requests. Based on our communication with the FDA on Friday, we concluded that there was not sufficient time fo GlobeNewswire ? 3 months ago RDGL +1.42% Vivos Inc. Submits the Application to the FDA for Authority to Initiate Human Clinical Trials Richland WA, June 28, 2024 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc. filed the application for an Investigational Device Exemption (“IDE”). The filing was an amendment, addressing the FDA comments to our previous application (Q211938/S001). Today’s IDE submission marks our first filing with the FDA following the grant of the FDA Breakthrough Device Designation for the Radiogel? Precision Radionuclide Therapy. We are appreciative of the improved communication with the FDA since rec GlobeNewswire ? 4 months ago RDGL +1.42% Radiogel? Precision Radionuclide Therapy? Receives FDA Breakthrough Device Designation Richland WA, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc is pleased to announce that the Food and Drug Administration has granted RadioGel Precision Radionuclide Therapy the designation as a Breakthrough Device pursuant to the FDA’s Breakthrough Devices Program. Dr. Mike Korenko stated “We are pleased with the FDA’s decision to grant Breakthrough Device Designation following our recent data submissions. The FDA did a very thorough review. The analysis in our Risk Manage GlobeNewswire ? 10 months ago RDGL +1.42% Performance Overview Trailing total returns as of 11/1/2024, which may include dividends or other distributions. Benchmark is S&P 500 Return RDGL S&P 500 YTD +68.33% +20.10% 1-Year +109.83% +36.60% 3-Year +21.70% +24.39%
